Equities Analysts Set Expectations for UNCY Q1 Earnings

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) – Stock analysts at Noble Financial issued their Q1 2027 earnings per share estimates for Unicycive Therapeutics in a note issued to investors on Wednesday, July 1st. Noble Financial analyst R. Leboyer expects that the company will earn $0.85 per share for the quarter. Noble Financial has a “Outperform” rating and a $50.00 price objective on the stock. The consensus estimate for Unicycive Therapeutics’ current full-year earnings is ($0.32) per share. Noble Financial also issued estimates for Unicycive Therapeutics’ Q2 2027 earnings at $0.91 EPS, Q3 2027 earnings at $1.18 EPS and Q4 2027 earnings at $1.38 EPS.

Other equities research analysts have also recently issued research reports about the company. Benchmark lowered their target price on Unicycive Therapeutics from $18.00 to $13.00 and set a “speculative buy” rating on the stock in a report on Wednesday. B. Riley Financial reissued a “buy” rating and issued a $22.00 price target on shares of Unicycive Therapeutics in a report on Tuesday. Wall Street Zen downgraded Unicycive Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, June 27th. HC Wainwright decreased their price objective on Unicycive Therapeutics from $22.00 to $15.00 and set a “buy” rating on the stock in a research note on Tuesday. Finally, Weiss Ratings upgraded Unicycive Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, June 9th. Six research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $27.40.

Unicycive Therapeutics Price Performance

Shares of NASDAQ UNCY opened at $5.28 on Thursday. Unicycive Therapeutics has a 12-month low of $3.71 and a 12-month high of $8.74. The company has a market capitalization of $144.62 million, a PE ratio of -2.39 and a beta of 1.80. The firm’s 50-day moving average is $7.46 and its two-hundred day moving average is $6.82.

Unicycive Therapeutics (NASDAQ:UNCY) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($0.54) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.08).

Institutional Trading of Unicycive Therapeutics

Hedge funds have recently bought and sold shares of the company. State Street Corp raised its holdings in Unicycive Therapeutics by 19.0% in the 4th quarter. State Street Corp now owns 65,227 shares of the company’s stock valued at $376,000 after acquiring an additional 10,400 shares during the last quarter. Lazard Asset Management LLC acquired a new stake in shares of Unicycive Therapeutics during the second quarter worth $55,000. JPMorgan Chase & Co. boosted its holdings in shares of Unicycive Therapeutics by 11,698.4% during the second quarter. JPMorgan Chase & Co. now owns 21,709 shares of the company’s stock worth $104,000 after purchasing an additional 21,525 shares during the last quarter. Renaissance Technologies LLC purchased a new stake in shares of Unicycive Therapeutics in the first quarter valued at $161,000. Finally, Bank of America Corp DE grew its position in shares of Unicycive Therapeutics by 19,327.6% in the first quarter. Bank of America Corp DE now owns 29,530 shares of the company’s stock valued at $194,000 after purchasing an additional 29,378 shares during the period. Institutional investors and hedge funds own 40.42% of the company’s stock.

Unicycive Therapeutics News Summary

Here are the key news stories impacting Unicycive Therapeutics this week:

• Positive Sentiment: Noble Financial and Brookline Capital Markets reiterated a constructive long-term view, with Noble assigning an Outperform rating and $50 target while modeling strong 2027 earnings and Brookline raising its FY2030 EPS estimate. Analyst target update
• Positive Sentiment: Despite the FDA setback, the company said the agency did not raise concerns about OLC’s clinical efficacy or safety data and requested no additional clinical data, which leaves the door open for a future resubmission. FDA CRL summary
• Neutral Sentiment: Unicycive said it is in ongoing discussions with the FDA over labeling and packaging and remains optimistic about resolving the manufacturing issues, but there is still no clear timeline for approval. Investigation notice
• Negative Sentiment: Multiple law firms launched securities-fraud investigations into Unicycive after the FDA rejection, adding legal and reputational overhang for shareholders. Investor alert
• Negative Sentiment: Benchmark, Noble Financial, and HC Wainwright all lowered price targets, reflecting reduced near-term confidence after the regulatory setback. Price target cuts

Unicycive Therapeutics Company Profile

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.